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Abstract
HIV-1 associated neurocognitive disorders (HAND) develop during progressive HIV-1 infection and affect up to 50% of
infected individuals. Activated microglia and macrophages are critical cell populations that are involved in the pathogenesis
of HAND, which is specifically related to the production and release of various soluble neurotoxic factors including
glutamate. In the central nervous system (CNS), glutamate is typically derived from glutamine by mitochondrial enzyme
glutaminase. Our previous study has shown that glutaminase is upregulated in HIV-1 infected monocyte-derived-
macrophages (MDM) and microglia. However, how HIV-1 leads to glutaminase upregulation, or how glutaminase expression
is regulated in general, remains unclear. In this study, using a dual-luciferase reporter assay system, we demonstrated that
interferon (IFN) a specifically activated the glutaminase 1 (GLS1) promoter. Furthermore, IFN-a treatment increased signal
transducer and activator of transcription 1 (STAT1) phosphorylation and glutaminase mRNA and protein levels. IFN-a
stimulation of GLS1 promoter activity correlated to STAT1 phosphorylation and was reduced by fludarabine, a chemical that
inhibits STAT1 phosphorylation. Interestingly, STAT1 was found to directly bind to the GLS1 promoter in MDM, an effect that
was dependent on STAT1 phosphorylation and significantly enhanced by IFN-a treatment. More importantly, HIV-1 infection
increased STAT1 phosphorylation and STAT1 binding to the GLS1 promoter, which was associated with increased glutamate
levels. The clinical relevance of these findings was further corroborated with investigation of post-mortem brain tissues. The
glutaminase C (GAC, one isoform of GLS1) mRNA levels in HIV associated-dementia (HAD) individuals correlate with STAT1
(p,0.01), IFN-a (p,0.05) and IFN-b (p,0.01). Together, these data indicate that both HIV-1 infection and IFN-a treatment
increase glutaminase expression through STAT1 phosphorylation and by binding to the GLS1 promoter. Since glutaminase
is a potential component of elevated glutamate production during the pathogenesis of HAND, our data will help to identify
additional therapeutic targets for the treatment of HAND.
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Introduction
HAND develop during progressive HIV-1 infection and are
characterized by cognitive impairments, behavioral disorders and
potential progressive motor abnormalities as a consequence of
neuronal damage during prolonged inflammation in the CNS [1].
Activated macrophages and microglia are critical to the patho-
genesis of HAND, as they are known to contribute to neuronal
injury through the production and release of various soluble
neurotoxic factors including glutamate [2,3,4]. Although gluta-
mate is a neurotransmitter involved in vital physiologic processes,
excess extracellular glutamate can lead to neuronal damage and
death [5]. Specifically relevant to HAND, HIV-1 infected
macrophages are a great source of extracellular glutamate [6,7],
however, the mechanisms of excess glutamate levels associated
with HIV-1 infection remain unclear.
Our previous work has demonstrated that HIV-1-infected
MDM and microglia produce more extracellular glutamate than
uninfected cells [8,9], an effect that is dependent on mitochondrial
glutaminase [10]. In the CNS, mitochondrial glutaminase is a key
enzyme that converts glutamine to glutamate, an enzymatic
process that has the potential to cause neuronal toxicity [8,11].
Kidney-type glutaminase (KGA) is highly expressed in the brain
[12]; it has various isoforms generated through tissue-specific
alternative splicing, including GAC, a KGA variant [13]. Human
GAC mRNA is produced by alternative splicing of GLS1 gene,
joining exons 1–15, while the human KGA mRNA has exons 1–
14 and 16–19; the resulting protein of human GAC shares much
of the functional human KGA regions (exon 1–14), but contains
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isoform is specifically upregulated in MDM and microglia during
HIV infection [9,15]. Despite extensive studies of upstream
molecular stimuli, particularly those that are responsible for
HIV-1-mediated GAC upregulation and glutamate overproduc-
tion, are still obscure.
HIV-1 invasion of the CNS and infection of macrophages and
microglia may lead to cellular activation and subsequent release of
cytokines, chemokines, and growth factors that include type I
IFNs, IFN-a and IFN-b [16]. All type I IFNs interact with the
IFN-a receptor (IFNAR) [17], which couples to a uniform signal
transduction cascade. IFN-IFNAR binding triggers receptor
dimerization and activation [18], leading to phosphorylation of a
tyrosine residue on IFNAR [19], tyrosine kinase JAK1/2 [20] and
STAT [21,22], ultimately leading to the dimerization of STAT
[23]. Activated STAT dimers then dissociate from the receptor,
translocate to the nucleus and bind to the interferon stimulated
response elements (ISRE) of IFN-stimulated genes [24]. Our
previous study shows that type I IFNs regulate the STAT pathway
in HIV-1-infected MDM [25]; this innate immune response has
been increasingly recognized to associate with the progression of
HAND [26].
Regulation of glutaminase promoter activity remains to be fully
elucidated. Rat GLS1 promoter was previously cloned and
functionally analyzed in 2001 [27,28]. Furthermore, human
GLS2 promoter was described in 2003 [29]. In the present
report, we cloned and characterized the human GLS1 promoter.
Using a MDM model, we studied the mechanism of transcrip-
tional activation of GLS1 specifically by IFN-a. We found that
IFN-a induced STAT1 phosphorylation and subsequently en-
hanced STAT1 binding to the GLS1 promoter. More importantly,
HIV-1 infection induced STAT1 to bind to the GLS1 promoter
thereby leading to glutamate overproduction. Understanding
glutaminase regulation and its effect on glutamate production in
HIV-1 infection may elucidate further information on how HIV-1
infection induces neurotoxicity, ultimately helping to develop new
therapies.
Results
IFN-a Specifically Activates the GLS1 Promoter
To study the gene regulation of human glutaminase, we first
looked at the GLS1 promoter. A GLS1 promoter construct was
created from a BAC clone PR11-413B20 and ligated into a dual-
luciferase system vector, pGL-3 basic (Fig. 1A). Analysis of the
promoter sequence revealed putative binding sites for a number of
transcription factors (Fig. 1B). Notably, the hallmark TATA box,
which is usually located in the region of –25 to –30, was found at -
111 to –108 (TAAT), with a putative CAAT box at –76 to –72.
Other transcription factors that have the potential to bind to the
promoter include activator protein 1 (AP-1), nuclear factor 1 (NF-
1) and specificity protein 1 (SP-1), which are typically constitutively
active in cells. When we looked for the inducible transcription
factors, we found up to 8 sequences predicted to be STAT binding
sites, indicating the factors that regulate STAT activation might
have the potential to regulate the GLS1 promoter.
Next, we used a panel of cytokines in the stimulation of cells to
determine the possible factors that regulate the GLS1 promoter.
We transiently co-transfected HEK 293T cells with GLS1
promoter-driven Firefly luciferase reporter plasmid and pRL-
SV40 that served as an internal control for transfection efficiency.
Of all the cytokines used, including IFN-a (100 U/ml), IFN-c
(100 ng/ml), IL-1b (10 ng/ml), IL-6 (10 ng/ml), IL-10 (25 ng/
ml), TRAIL (50 ng/ml) and TNF-a (50 ng/ml), only IFN-a
significantly increased (2-3-fold) the human GLS1 promoter
activity (Fig. 2A). To confirm the effect of IFN-a, we examined
different doses of IFN-a treatment and performed a time course to
determine the effect on GLS1 promoter activity. We found that
the increase in GLS1 promoter activity by IFN-a is dose-
dependent (Fig. 2B) from 0 to 100 U/ml and time-dependent
(Fig. 2C) from 0 to 24 hours. The effect of IFN-a on GLS1
promoter activity is specific because blocking IFN-a with
neutralizing antibodies abolished IFN-a-induced GLS1 promoter
activation (Fig. S2). Similarly, rat IFN-a activated the glutaminase
promoter in rat astrocytes, suggesting regulation of glutaminase
promoter by IFN-a is not limited to humans (Fig. S1A-C).
IFN-a Induces STAT1 Phosphorylation and Subsequently
Increases Glutaminase Expression and Glutamate
Production in MDM
IFN-a is known to regulate gene expression through the STAT
signaling pathway [24]. To further study the mechanism of IFN-a-
activated GLS1 promoter activity, we determined STAT1
phosphorylation following treatment of MDM with varying doses
of IFN-a for 24 hours. The STAT1 protein exists as a pair of
isoforms, STAT1a (91 kDa) and the splice variant STAT1b (84
kDa). The p-STAT1 and STAT1 antibodies used in our study
detected both isoforms. Protein analysis showed that both p-
STAT1 (Tyr 701) and total STAT1 were increased by IFN-a in a
dose-dependent manner (Fig. 3A, C, D). Similarly, GAC protein
levels were upregulated by IFN-a treatment in a dose-dependent
manner, whereas KGA was moderately upregulated only at higher
doses (300 and 1000 U/ml) of IFN-a treatment (Fig. 3A, E, F).
Consistent with the human data, rat astrocytes treated with rat
IFN-a had similar upregulation of GAC, KGA (not significant)
and total GLS1 mRNA, detected by the specific primers,
suggesting that the regulation of glutaminase by IFN-a is not
species-specific (Fig. S3). The intracellular glutamate levels, as
determined by a glutamate oxidase assay kit, were increased
following IFN-a treatment, indicating the upregulated GAC and
KGA had functional output to the cells (Fig. 3B). Notably, in
MDM, the peak concentration of IFN-a to upregulate GAC and
produce glutamate is 1000 U/ml, however, for GLS1 promoter
activity detection in 293T cells, the peak concentration is 100 U/
ml (Fig. 2B), this inconsistency may be due to their differential
expression of type I IFNs receptor IFNR or related signaling
intermediates in two different cell models.
To determine the mechanism of glutaminase upregulation, we
investigated whether STAT1 phosphorylation is involved in the
glutaminase upregulation. STAT1 phosphorylation correlated
significantly with the protein levels of GAC and KGA (p,0.01),
suggesting the possible involvement of p-STAT1 (Fig. 3G, H). To
test whether STAT1 phosphorylation was required in IFN-a-
induced glutaminase regulation, we used the chemical inhibitor
fludarabine, which specifically inhibits STAT1 phosphorylation
[30]. Fludarabine (1mM) pretreatment dramatically decreased
(80% reduction) IFN-a-induced STAT1 phosphorylation in HEK
293T cells (Fig. 3I). The weaker p-STAT1b (84 kDa) in 293T cells
compared with MDM (Fig. 3A) revealed a cell type-specific
expression pattern of the STAT1 isoforms. Following the
inhibition of STAT1 phosphorylation, fludarabine significantly
decreased the IFN-a-induced GLS1 promoter activity in HEK
293T cells (Fig. 3J); similar data was found in rat GLS1 promoter
assays performed in rat astrocytes (Fig. S1D). Collectively, these
data demonstrate that IFN-a activates the GLS1 promoter and
upregulates glutaminase through STAT1 phosphorylation.
Glutaminase Promoter Regulation by IFN-a and STAT1
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e32995Figure 1. Human GLS1 promoter construct and sequence analysis. (A). Schematic diagram of the human GLS1 promoter-driven luciferase
reporter construct. The construct contains the Firefly luciferase coding sequence (black) with regions of the promoter (blank) and the 5’ UTR (shaded).
The restriction enzymes used for cloning are shown. (B). Sequence analysis of the human GLS1 promoter. The TSS is designated as +1. The 5’ UTR is
shown in gray. The coding sequence is underlined. Putative transcription factor binding sites along the promoter sequence are highlighted in
different colors, with their corresponding transcription factors shown on top of the sequence. Highlighted in red: TATA box, dark green: CAAT box,
pink: AP-1, blue: SP-1, bright green: STAT, grey: 5’ UTR glutaminase; font color in blue: NF-1.
doi:10.1371/journal.pone.0032995.g001
Figure 2. IFN-a specifically activates human GLS1 promoter. HEK 293T cells were co-transfected with the human GLS1 promoter construct
and pRL-SV40. 24 hours later, the cells were treated with either various individual cytokines for another 24 hours (A), IFN-a of varying doses for 24
hours (B), or with 100 U/ml IFN-a for varied time lengths (C). In (A), 100 U/ml IFN-a, 100 ng/ml IFN-c, 10 ng/ml IL-1b, 10 ng/ml IL-6, 25 ng/ml IL-10,
50 ng/ml TRAIL, or 50 ng/ml TNF-a was used. Luciferase activity in the lysates was measured by luminescence detection. Renilla luciferase was used
as internal control to normalize transfection efficiency. The data are representative of three independent experiments and are the means of triplicate
samples. #,p ,0.05, *,p ,0.01, **, p,0.001 in comparison to control.
doi:10.1371/journal.pone.0032995.g002
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e32995Figure 3. STAT1 phosphorylation is required for IFN-a to activate the GLS1 promoter and induce glutaminase expression and
function. (A). MDM were treated with different doses of IFN-a for 24 hours, then p-STAT1 (Tyr 701), STAT1, KGA and GAC were detected by Western
blot. b-actin was used as a loading control. (B). Intracellular glutamate was detected using the Amplex
H Red Glutamic Acid/Glutamate Oxidase Assay
Kit. The data are representative of three independent experiments using three different donors and are the means of triplicate samples. (C-F). Levels
of p-STAT1 (C), STAT1 (D), GAC (E) and KGA (F) in Western blot (A) were normalized as a ratio to b-actin and shown as fold change relative to control.
Results are shown as the average 6 SEM of three independent experiments with three different donors, (G, H). Correlation of p-STAT1 with GAC (G)
and p-STAT1 with KGA (H) in representative donor are shown. (I, J). HEK 293T cells were co-transfected with the GLS1 promoter construct and pRL-
SV40. 24 hours later, the cells were pretreated with 1 mM fludarabine or 1:10,000 DMSO for 1 hour, then treated with or without 100 U/ml IFN-a for 24
hours. (I). p-STAT1 and STAT1 were detected by Western blot, b-actin was used as a loading control. (J). Luciferase activity in the lysates was measured
by luminescence detection. Renilla luciferase was used to normalize transfection efficiency. The data are representative of three independent
experiments and are the means of triplicate samples. #,p ,0.05. *, p,0.01, **, p,0.001 when compared to control.
doi:10.1371/journal.pone.0032995.g003
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Treated Cells
Since the human GLS1 promoter contains several putative
STAT1 binding sites (Fig. 1B, 4A), and STAT1 phosphorylation
was found to correlate with IFN-a-induced glutaminase upregula-
tion (Fig. 3), we used a chromatin immunoprecipitation (ChIP)
assay to determine the binding of the p-STAT1 to the GLS1
promoter. The rat glutaminase promoter also had several putative
STAT binding sites (Fig. S4A). To identify the key promoter
sequences that respond to IFN-a, we used serial deletions of the rat
promoter construct. To our surprise, even the shortest promoter
sequence (2401 +110) responded to IFN-a treatment (Fig. S4B).
There were two putative STAT1 binding sites in the shortest
promoter construct, which were subsequently targeted for the
ChIP assay. We used STAT1 antibody to immunoprecipitate the
protein-DNA complex from cellular lysates of rat astroyctes and
used RT-PCR to detect the glutaminase promoter sequence. IFN-
a dramatically increased GLS1 promoter signaling in the protein-
DNA complex, suggesting that there is direct binding of STAT1
with the rat glutaminase promoter (Fig. S4C). Next, in human
cells, the putative STAT1 binding site (2334 to 2326) that is
similarly positioned to one of those we detected in the rat, was used
for the ChIP assay. MDM were treated with IFN-a (100 U/ml) for
1 hour and STAT1, p-STAT1 (Tyr701), or IgG antibody was used
to immunoprecipitate the protein-DNA complex. Primers specific
to the STAT1 binding site located at 2334 to 2326 were used for
real time RT-PCR. The precipitated DNA by STAT1 or p-
STAT1 antibody was significantly increased in IFN-a treated cell
lysates, but not by the negative control rabbit IgG antibody,
indicating that the binding of STAT1 or p-STAT1 with the
human GLS1 promoter was significantly increased following IFN-
a treatment (Fig. 4B). To determine whether the binding of
STAT1 with the human GLS1 promoter was dependent on
STAT1 phosphorylation, fludarabine (1 mM) was used to pretreat
MDM for 1 hour before the ChIP assay. As expected, fludarabine
pretreatment attenuated IFN-a-induced STAT1-GLS1 promoter
DNA complex, suggesting that binding of STAT1 to the human
GLS1 promoter was dependent on STAT1 phosphorylation
(Fig. 4C).
Increased STAT1 Binding to the GLS1 Promoter in HIV-1
Infected MDM
Our previous study shows that GAC is increased [15] and
STAT1 is activated [25] in HIV-infected MDM. To test whether
HIV infection induces p-STAT1 binding to the GLS1 promoter
and subsequently increases GAC expression, we used a ChIP assay
to determine the p-STAT1-GLS1 promoter DNA complex in
HIVADA-infected and uninfected MDM. The HIV-1 replication
levels were confirmed by RTase assay (Fig. 5B). p-STAT1 was
significantly induced to bind to the GLS1 promoter in HIVADA-
infected MDM (Fig. 5A). This increase of the p-STAT1-GLS1
promoter DNA complex upon HIV-1 infection was associated
with a four-fold and two-fold increase of p-STAT1 and STAT1
protein levels, respectively, compared with uninfected cells
(Fig. 5C). Consequently, both intracellular (Fig. 5D) and
extracellular glutamate levels (Fig. 5E) were increased, indicating
that increased p-STAT1 binding to the GLS1 promoter might
contribute to the excess levels of glutamate seen in HIV-1-infected
MDM. To further determine the mechanism of STAT1 activation
in HIV-1-infected MDM, we detected the expression of type I
IFNs and found that both IFN-a and IFN-b mRNA levels were
significantly increased in HIV-1 infected MDM (Fig. 5F). More
importantly, IFN-a and IFN-b neutralizing antibodies, which were
able to block the binding of type I IFNs with their receptor IFNR
and the downstream STAT1 phosphorylation (60% reduction,
[25]Fig. 5H), significantly attenuated both mRNA (Fig. 5G) and
protein levels (Fig. 5H and I) of GAC induced by HIV-1 infection.
Together, these results demonstrate that HIV-1 induces type I
IFNs response, which in turn activates STAT1 and induces gene
transcription of glutaminase.
Figure 4. STAT1 binds directly with the GLS1 promoter in IFN-a
treated MDM. (A). The predicted STAT1 binding sites in the human
GLS1 promoter, TSS is designated as +1. (B). MDM were treated with
100 U/ml IFN-a for 1 hour, then ChIP assay was performed using
digested chromatin, p-STAT1 (Tyr 701) and STAT1 antibodies, or IgG
antibody as a negative control. Purified DNA was analyzed by
quantitative real-time PCR using specific primers. The amount of
immunoprecipitated DNA is represented as signal relative to the total
amount of input chromatin. The data are representative of three
independent experiments using three different donors. #,p ,0.05,
*, p,0.01 in comparison with control. (C). MDM were pretreated with
1 mM fludarabine or 1:10,000 DMSO for 1 hour, then treated with or
without 100 U/ml IFN-a for another hour. ChIP assay was performed
using p-STAT1 antibody as in (B). The data are representative of two
independent experiments using two different donors. *, p,0.01 in
comparison with control that were treated with DMSO only; #,p ,0.05
in comparison to cells treated with IFN-a and DMSO.
doi:10.1371/journal.pone.0032995.g004
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PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e32995Figure 5. STAT1 binds directly with the GLS1 promoter in HIV-1 infected MDM. (A-E). MDM were infected with or without HIV-1ADA for 5
days. (A). ChIP was performed using p-STAT1 (Tyr 701) antibody; IgG was used as a negative control. (B). Supernatants were tested for RTase activity.
(C). p-STAT1 and STAT1 were detected by Western blot with b-actin used as a loading control. (D). Glutamate was detected in supernatants by HPLC.
(E). Intracellular glutamate was detected using the Amplex
H Red Glutamic Acid/Glutamate Oxidase Assay Kit. The data (A-E) are representative of
three independent experiments using three different donors. (F) Human MDM were infected with HIV-1 for 5 days, then total RNA was collected. IFN-
a and IFN-b mRNA levels were determined by real-time RT-PCR. Results shown are representative of three independent experiments using three
different donors and are means of triplicate samples. (G-I) Human MDM were infected with HIV-1 for 5 days in the presence of IgG or IFN-a/IFN-b
neutralizing antibodies. Total RNA and cell lysates were collected and GAC mRNA (G) and protein (H and I) levels were determined by real time RT-
PCR and Western blot, respectively. For quantification, GAC expression were normalized as a ratio to b-actin and shown as fold change relative to IgG
control . Results (F, I) are shown as the average 6 SEM of three independent experiments with three different donors, #,p ,0.05, *, p,0.01,
**, p,0.001, when compared with uninfected MDM or IgG control.
doi:10.1371/journal.pone.0032995.g005
Glutaminase Promoter Regulation by IFN-a and STAT1
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e32995Significant Correlation Between STAT1, IFN-a, IFN-b and
GAC mRNA Levels in a Set of Brain Tissues Including HAD
Patients
To further investigate the clinical relevance of STAT1 and
GLS1 to HAD, we analyzed STAT1 and GLS1 mRNA levels
from post-mortem brain tissue collected from HAD patients, HIV
serum-positive patients without dementia, and HIV serum
negative individuals. We have previously reported that protein
levels of GAC and STAT1 were significantly increased in HAD
brain tissues compared with HIV serum negative individuals [9].
Using the mRNA from the same sets of brain tissues, we found
that STAT1 mRNA levels were significantly increased in HAD
patients compared to HIV serum negative individuals and HIV
serum-positive patients without dementia (p,0.05) (Fig. 6A).
Furthermore, significant correlations were found between GAC
and STAT1 (p=0.0014), IFN-a (p=0.0111), and IFN-b
(p=0.0022) (Fig. 6B, C and D). This clinical relevance of STAT1
and type I IFNs in association with GAC strongly indicates that
STAT1 and type I IFNs play important roles in GAC expression
in HAD.
Discussion
Little is known about how glutaminase expression is regulated.
In our study, we used a dual-luciferase reporter assay system to
demonstrate that IFN-a specifically activated the GLS1 promoter
(Fig. 2, S1). The elevated GLS1 promoter activity correlated with
increased levels of GLS1 mRNA and protein (Fig. 3, S3).
Furthermore, increased glutaminase expression by IFN-a treat-
ment was correlated with STAT1 phosphorylation and could be
reduced by fludarabine, a chemical that inhibits STAT1
phosphorylation (Fig. 3). In a well-characterized model of HIV-1
infection in human MDM, we have shown that IFN-a treatment
or HIV-1 infection of MDM activates STAT1 phosphorylation to
bind to and upregulate the GLS1 promoter activity, and
subsequently increased glutaminase and glutamate production
(Fig. 4, 5). Importantly, blocking type I IFNs with neutralizing
antibodies in HIV-1-infected MDM blocked GAC upregulation at
both mRNA and protein levels (Fig. 5G, H and I), confirming the
critical role of type I IFNs on HIV-1-induced glutaminase
upregulation. These data suggest that IFN-a phosphorylates and
activates STAT1; STAT1 binds with GLS1 promoter and
enhances promoter activity, which increases glutaminase gene
transcription. Since glutaminase converts glutamine into gluta-
mate, which is a neurotoxin when in excess levels, IFN-a may have
adverse effects through glutamate-mediated excitotoxicity in
addition to its traditional cytotoxic activity in antigen presenting
cells. Therefore, we propose that the findings here may have
potential implications for understanding the pathogenesis of
HAND, particularly the neurotoxic processes that involve
significant production of inflammatory cytokines and soluble
factors including glutamate.
The clinical relevance of this observation is further corroborated
with the investigation of post-mortem brain tissues. The tissue
GAC mRNA levels were significantly correlated with STAT1,
IFN-a and IFN-b (Fig. 6). These important data extend our
previous observation that GAC is correlated with STAT1 [9] and
the physiological indication of this finding is significant because
elevated STAT1 and type I IFNs levels are not only observed in
HAD, but also in many other neurodegenerative diseases
Figure 6. Significant correlation between STAT1 and GAC mRNA levels in brain tissues of HAD patients. Total RNA from post-mortem
brain tissue collected from HAD patients, HIV serum-positive patients without dementia, and HIV serum negative individuals were extracted and
subjected to real time RT-PCR for STAT1, GAC, IFN-a2 and IFN-b. GAPDH expression was used as an internal control. (A) Levels of STAT1 are
normalized as a ratio to GAPDH and shown as fold change relative to the average of HIV serum negative controls. Results are shown as the average 6
SEM, #,p ,0.05. Correlation of GAC with STAT1 (B), IFN-a2 (C) and IFN-b (D) mRNA levels was determined by Spearman correlation.
doi:10.1371/journal.pone.0032995.g006
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32995[31,32,33,34] though the exact functions of STAT1 and type I
IFNs in diseases remains to be elucidated. In addition to STAT1
and type I IFNs, dysregulated glutaminase has also been indicated
in a few animal models of neurodegenerative diseases. Microglia
glutaminase has been suggested to have neurotoxic potentials in
MECP2 knockout mice, which underlined the potential patho-
genic role of dysregulated glutaminase in the CNS [35]. Because
IFNs are released in the late stage of HIV-1 infection [36,37], and
HIV-1 infection could also increase glutaminase expression and
glutamate production [31,32], the identification of type I IFNs and
STAT1 as key regulators of glutaminase expression could provide
critical links between HIV-1 infection, innate immune response
and the dysregulation of glutaminase in infected macrophages and
microglia.
Eukaryotic transcription and translation regulation are com-
plex. For glutaminase, the control of expression may occur at the
transcriptional, post-transcriptional, translational or post-transla-
tional level. In an attempt to characterize the GLS1 promoter
regulatory sequences, we cloned the promoter region, up to
2490 bp upstream of the transcription initiation site (TSS) (Fig. 1).
Surprisingly, this extensive region contains many putative binding
sites for STAT1, indicating potential STAT1-mediated regulation
of the glutaminase promoter activity. As expected, IFN-a, which is
known to increase STAT1 phosphorylation and nuclear translo-
cation, specifically upregulated GLS1 promoter activity (Fig. 2,
S1). Previously, it was reported that longer 166GCA microsatellite
alleles in the promoter region correlate with higher activity of
glutaminase in vivo [38]. In addition, acidic medium increases
glutaminase expression through stabilization of KGA mRNA [28].
The 39-UTR of KGA mRNA contains a direct repeat of an 8
nucleotide, AU-rich sequence that functions as a pH-response
element (pHRE), which binds multiple RNA-binding proteins, to
impart a pH-responsive stabilization and to thereby protect the
KGA mRNA [39,40]. Moreover, c-Myc suppression of miR-23
has been identified as a mechanism to enhance glutaminase
expression through post-transcriptional regulation [41]. To our
knowledge, this is the first report demonstrating that glutaminase
transcription and function are under the control of STAT1 and
type I IFNs.
The presence of multiple transcripts for glutaminase genes and
the simultaneous expression of several different glutaminase
isoforms reported in mammalian tissues and cells indicate that
post-transcriptional splicing also exists [13,14,42]. However,
exactly how splicing occurs and the overall significance of the
glutaminase isoforms is still unclear. GAC regulation has recently
been observed in a variety of tumors [43], indicating that the GAC
isoform is possibly an important component of tumor cells, and
modulation of GAC activity may provide a therapeutic avenue for
cancer.
Cytokines typically regulate gene promoters through directing
transcription factors to their binding sites in the promoter region.
The proinflammatory cytokine IL-6 upregulates calcium-sensing
receptor gene transcription via STAT1/3 [44]. IFN-c upregulates
MUC4 in pancreatic cancer cells through STAT1 expression [45].
Notably, cytokines other than type I IFNs have been reported to
regulate glutamate metabolism. TNF-a induces neurotoxicity by
inhibiting glutamate uptake through the glutamate transporter of
astroglial cells [46] as well as by upregulating glutaminase with
concurrent release of glutamate through hemichannels in activated
mouse microglia [47]. On the other hand, TGF-b increases
expression of glutaminase in a porcine kidney cell line [28]. In our
study we found that IFN-a specifically activated the GLS1
promoter through the STAT1 pathway in human macrophages
[48]. Regulation of the GLS1 promoter by IFN-a or HIV-1
infection is specific to STAT1 because when we used STAT3
antibody in the ChIP assay we found that neither IFN-a nor HIV-
1 infection significantly increased binding between STAT3 and
the GLS1 promoter (data not shown). Furthermore, STAT1 plays
an important role in the cellular response to IFN-a [49]. In our
study STAT1 binds to the GLS1 promoter to increase glutaminase
for glutamate production in HIV-1 infected MDM (Fig. 5D, E).
Although there are multiple predicted STAT1 binding sites in
both the rat and human GLS1 promoter (Fig. 4A and S2A), in this
study we focused on the two sites that are closest to the translation
start site (Fig. 4B, C, Fig. 5A and Fig. S3C). The function of other
STAT1 putative binding sites needs to be further investigated.
The doses of IFN-a used in our in vitro experiments were
between 10 and 1000 U/ml. It is possible that these concentra-
tions are higher than that would be detected in blood. However,
high plasma levels of IFN-a can be detected during acute HIV
infection [48]. Furthermore, it is likely that much HIV-1
pathogenesis occurs in the tissue where type I IFNs may be more
concentrated than in the circulatory system. Our data demonstrate
that IFN-a, at concentrations as low as 10 U/ml, was sufficient to
increase phosphorylated STAT1 (Fig. 3A and C), promoter
activity (Fig. 2B) and GAC expression (Fig. 3A and C) compared
with control. Therefore, we used IFN-a at concentrations between
10 and 1000 U/ml for a dose-response curve and chose 100 U/ml
as a representative dose for treatment throughout the text.
In conclusion, we found that IFN-a activates STAT1 to bind to
and activate the GLS1 promoter in HIV-1-infected macrophages.
This binding results in the upregulation of glutaminase and a
subsequent increase in glutamate production, which may drive the
excitotoxicity of neurons during HIV infection. We propose this
finding has potential implications for understanding the patho-
genesis of HAND. Dysregulated glutaminase and its potential
neurotoxic process stemming from innate immune activation raise
important questions about how to regulate the innate immune
response in an effective and specific way without harming the
vulnerable neuronal tissues with excitotoxicity.
Materials and Methods
Reagents
Recombinant proteins and chemicals were obtained as follows:
IFN-a2, IFN-b and IFN-a neutralizing antibody (PBL Interferon
Source, Piscataway, NJ); IL-1b, IL-6, IL-10, TNF-a, IFN-c, Trail,
and IFN-b neutralizing antibody (R&D systems. Minneapolis,
MN, USA); and fludarabine (Sigma-Aldrich, St, Louis, MO,
USA).
Plasmid Construct
Two overlapping segments with varying levels of GC content of
the human GLS1 promoter were amplified by PCR directly from
human bacterial artificial clone (BAC) PR11-413B20 (Invitrogen,
Carlsbad, CA) using PfuUltra
TM II Fusion HS DNA Polymerase
(Agilent Technologies, Santa Clara, CA) with the primers: 59-
CGGGGTACCGGAGCAAAAAGGAAGTCGAAGAGTAGAT-
CTGACAACCCAACCATAG-39 (sense for low GC content
section), 59-AAATGTACACCGATACTTCAAAAATAGTTTT-
GAATAGCAATGATTCCGTTAACGC-39 (antisense for low
GC content section), 59-CGGTGTACATTTAAAAAAAATA-
ATTTTTAAAAAAGAAAGCTGTCGTATTCTGGATTCCG-
C-39 (sense for GC rich section), 59-CCGCTCGAGGCCGC-
CGGGTCCGTCAGCGCCCGCTCAACAGGGGAGGATGC-
TCC-39 (antisense for GC rich section). The BAC plasmid was
initially denatured at 95uC for 3 min, followed by 30 cycles of
denaturing at 94uC for 30 s, primer annealing at 61uC for 30 s,
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Indianapolis, IN, USA) was used to add poly A for ligating the
PCR products to the pGEM-T easy vector with T4 ligase
(Promega, Madison, WI, USA). After the sequence was confirmed,
the two segments with varying levels of GC content were cut and
ligated to the pGL-3 vector (Promega) using the specific restriction
enzymes, KpnI, BsrGI and XhoI (New England Biolabs, Ipswich,
MA, USA).
Cell Culture, Transfection and Luciferase Reporter Assay
HEK 293T (ATCC, Mansassas, VA, USA) cells were cultured
in 24-well plates in Dulbecco’s modified Eagles medium (DMEM,
GIBCO Invitrogen Corp, Carlsbad, CA) with 10% heat-
inactivated fetal bovine serum (FBS) (GIBCO Invitrogen Corp)
and an antibiotic mixture containing penicillin and streptomycin.
24 hours after plating, cells were transfected with the pGL3-basic
or GLS1 promoter-driven Firefly luciferase reporter plasmid with
Lipofectamine
TM LTX and PLUS reagent (Invitrogen, Carlsbad,
CA). Cells were co-transfected with 5 ng of Simian Virus 40
promoter-driven Renilla luciferase (pRL-SV40) plasmid as a
control for transfection efficiency. 24 hours post-transfection, cells
were treated with cytokines for another 24 hours; then the Firefly
and Renilla luciferase were analyzed using a Dual-Luciferase
Reporter System (Promega) according to the manufacturer’s
instructions.
MDM and HIV-1 Infection
Human monocytes were cultured as adherent monolayers at a
density of 1.1 610
6 cells/well in 24-well plates and cultivated in
Dulbecco’s modified Eagles medium (DMEM, GIBCO Invitrogen
Corp) with 10% heat-inactivated pooled human serum (Cambrex
Bio Science, Walkersville, MD, USA), 50 mg/ml gentamicin,
10 mg/ml ciprofloxacin (Sigma-Aldrich) and 1000 U/ml highly
purified recombinant human macrophage colony stimulating
factor (MCSF) (a generous gift from Wyeth Institute, Cambridge,
MA, USA). Seven days after plating, MDM were infected with
laboratory HIV-1ADA strain at a multiplicity of infection (MOI) of
0.1 virus/target cell. The HIV-1ADA was isolated from the
peripheral blood mononuclear cells (PBMCs) of an infected
patient with Kaposi’s sarcoma [50]. For virus stock preparation,
supernatants of HIV-1ADA-infected MDM were collected. The
titers of the virus in the supernatants were determined as we
previously described [51]. For HIV-1 infection, viral stocks were
diluted into the desired MOI for overnight incubation with MDM.
On the second day, medium was removed and substituted with
MDM culture medium that was half-exchanged every two days.
Stock virus was screened for mycoplasma and endotoxin using
hybridization and Limulus amebocyte lysate assays, respectively.
Five days after infection, HIV-1-infected and replicated uninfected
MDM were harvested for ChIP and Western blot assays. Culture
supernatants were obtained and subsequently stored at -80uC until
a reverse transcriptase (RTase) assay could be performed.
Western Blot Analysis
Cell lysates from MDM or HEK 293T cells were prepared with
M-PER Mammalian Protein Extraction Buffer (Pierce, Rockford,
IL, USA). Protein concentration was determined using the BCA
Protein Assay Kit (Pierce). Protein (20 mg) was electrophoresed on
pre-cast 10% SDS-PAGE gels (Bio-Rad, Hercules, CA) and
transferred to an Immuno-Blot PVDF membrane (Bio-Rad).
Proteins on the membrane were incubated with purified primary
antibodies for total STAT1 or phospho-STAT1 (p-STAT1,
Tyr701) (Cell Signaling Technologies, Danvers, MA, USA), for
GAC or KGA (Dr. N. Curthoys, Colorado State University), or for
b-actin (Sigma-Aldrich) overnight at 4
oC followed by a horserad-
ish peroxidase-ligand secondary anti-rabbit or anti-mouse
(1:10000 dilution; Cell Signaling Technologies) antibody for 1 h
at room temperature. Antigen-antibody complexes were visualized
by enhanced chemiluminescence (Amersham Biosciences, Piscat-
away, NJ, USA) and captured with CL-X Posure
TM Film (Pierce).
For data quantification the films were scanned with a CanonScan
9950F scanner; the acquired images were then analyzed on a
Macintosh computer using the public domain NIH image
program (developed at the U.S. National Institutes of Health
and available on the internet at http://rsb.info.nih.gov/nih-
image/).
ChIP Assay
ChIP assay was performed using a SimpleChIPH Enzymatic
Chromatin IP Kit (#9003, Cell Signaling Technologies) according
to the manufacturer’s instructions. Quantitative PCR was
performed using one pair of primers corresponding to the STAT1
binding site located at -598 in the human GLS1 promoter: 5’-
CCTGCCAAACCTGCTGACC-3’ (sense), 5’-CCACTCTGG-
GAATTCGAG-3’ (antisense). Quantifications were normalized
to input.
Measurements of HIV-1 RTase
RT activity was determined in triplicate samples of cell culture
fluids. For this assay, 10 ml of supernatant was incubated in a
reaction mixture of 0.05% Nonidet P-40, 10 mg of poly(A)/ml,
0.25 mg of oligo(dT)/ml, 5 mM dithiothreitol, 150 mM KCl,
15 mM MgCl2, and [
3H]TTP in Tris-HCl buffer (PH 7.9) for 24
hours at 37uC. Radiolabeled nucleotides were precipitated with
cold 10% trichloroacetic acid on paper filters in an automatic cell
harvester and washed with 95% ethanol. Radioactivity was
estimated by liquid scintillation spectroscopy [52].
Intracellular and Extracellular Glutamate Analysis
Intracellular glutamate detection was performed with the
Amplex
H Red Glutamic Acid/Glutamate Oxidase Assay Kit from
Invitrogen following the manufacture’s procedure. HPLC analysis
for extracellular glutamate was performed as previously described
[8].
RT-PCR for Detection of Human GLS1, IFN-a and IFN-b
Total RNA was isolated with TRIzol Reagent (Invitrogen Corp)
and RNeasy Kit according to the manufacturer’s protocol (Qiagen
Inc.). Primers used for real-time RT-PCR include human STAT1
(Hs01014002),humanGAC(ID#528445:theforwardsequencewas
59-TATGGAAAAAAGTGTCACCTGAGTCA-39, the reverse
sequence was 59-GCTTTTCTCTCCCAGACTTTCCATT-39,
and the probe sequence was 59-AATGAGGACATCTCTA-
CAACTGTA-39), human IFN-a2 (Hs00265051_S1), human IFN-
b1 (Hs01077958S1_S1), human GAPDH (part #4310884E),
human b-actin (part #4333762), rat GLS1 (00561285_m1), rat
KGA (Rn01640312_m1), rat GAC (ID #792159: the forward
sequence was 59-CTTTGGACCATTGGACTATGAGAGT-39,
the reverse sequence was 59-AGGTGACACTTTTTTCCA-
CACTGT-39, and the probe sequence was 59-CTCCAGCAA-
GAACTTG-39) and rat GAPDH (Rn99999916_s1) from Applied
Biosystems Inc. Real-time RT-PCR was performed using the one-
step quantitative TaqMan assay in a StepOne Real-Time PCR
system (Applied Biosystems Inc.). Relative STAT1, GAC, IFN-a2,
andIFN-b1 mRNAlevelsweredeterminedandstandardizedwitha
GAPDH or b-actin internal control using comparative DDCT
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efficiencies and the results were similar.
Statistical Tests
Data was analyzed as means 6 standard deviation unless
otherwise specified. The data were evaluated statistically by the
analysis of variance (ANOVA), followed by the Tukey-test for
paired observations. Significance was considered to be less than
0.05 unless otherwise specified. All assays were performed at least
three times with triplicate or quadruplicate determinations for
each.
Ethics Statement
Primary rat astrocytes were made from embryonic day 14–15
rat embryos in accordance with ethical guidelines for care and use
of laboratory animals set forth by the National Institutes of Health
(NIH), with Institutional Animal Care and Use Committee
(IACUC) #: 04-097-01; MDM were used in full compliance with
the University of Nebraska Medical Center and NIH ethical
guidelines, with the Institutional Review Board (IRB) #: 162-93-
FB. We have the informed written consent from all participants
involved in this study.
Supporting Information
Figure S1 IFN-a specifically activates rat GLS1 promot-
er. Rat astrocytes were co-transfected with the rat GLS1
promoter construct and pRL-SV40. 24 hours later, the cells were
treated with either various individual cytokines for another 24
hours (A), IFN-a of varying doses for 24 hours (B), or with 100 U/
ml IFN-a for varied time lengths (C). In (A), 100 U/ml IFN-a,
100 U/ml IFN-b, 100 ng/ml IFN-c, 10 ng/ml IL-1b, 10 ng/ml
IL-6, 50 ng/ml TRAIL, or 50 ng/ml TNF-a was used. (D). 24
hours after transfection, cells were pretreated with 1 mM
fludarabine or 1:10,000 DMSO for 1 hour then treated with
IFN-a (100 U/ml) for 24 hours. Luciferase activity in the lysates
was measured by luminescence detection. Renilla luciferase was
used as internal control to normalize transfection efficiency. The
data are representative of three independent experiments and are
the means of triplicate samples. #,p ,0.05, *,p ,0.01,
**, p,0.001 in comparison to control.
(TIF)
Figure S2 Type I IFN neutralizing antibodies block IFN-
a-induced GLS1 promoter activation. HEK 293T cells were
co-transfected with the human GLS1 promoter construct and
pRL-SV40. 24 hours later, the cells were pre-treated with IgG or
IFN-a/IFN-b neutralizing antibodies for 1 hour then treated with
IFN-a (100 U/ml) for 24 hours. Luciferase activity in the lysates
was measured by the luminescence detection. Renilla luciferase
was used as internal control to normalize transfection efficiency.
The data are representative of two independent experiments and
are the means of triplicate samples. #,p ,0.05.
(TIF)
Figure S3 glutaminase mRNA was increased in IFN-a
treated rat astrocytes. Rat astrocytes were treated with the
indicated doses of IFN-a for 24 hours. Real-time RT-PCR was
used to detect KGA, GAC or total GLS1. KGA, GAC or total
GLS1 expression were normalized to GAPDH and shown as fold
change relative to the untreated control. Results are shown as the
average 6 SEM of two independent experiments with two
different donors. #,p ,0.05, *,p ,0.01, **, p,0.001 when
compared to control.
(TIF)
Figure S4 STAT1 binds directly with the GLS1 promoter
in IFN-a treated rat astrocytes. (A). The predicted STAT1
binding sites in the rat GLS1 promoter. TSS is designated as +1.
(B) Rat astrocytes were co-transfected with rat GLS1 promoter
constructs with serial deletion and pRL-SV40. 24 hours later, the
cells were treated with 100 U/ml IFN-a for 24 hours. Luciferase
activity was measured and analyzed. The data are representative
of three independent experiments with three different donors.
*, p,0.01, **, p,0.001 in comparison to control. (C). Rat
astrocytes were treated with 100 U/ml IFN-a for 1 hour, then
ChIP assay was performed using STAT1 antibody. IgG antibody
was used as a negative control, whereas histone H3 antibody was
used as a positive control. Purified DNA was amplified by PCR
using specific primers. The PCR products were analyzed on 2%
agarose gel.
(TIF)
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